Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Health and Pharmaceutical (IJHP)
Najirman
Departemen Studi Penyakit Dalam, Divisi Reumatologi, Fakultas Kedokteran, Universitas Andalas, Indonesia
Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Management of Arthritis Associated with Inflammatory Bowel Disease (IBD): A Systematic Review of Conventional and Targeted Therapies Iqbal Habibie; Najirman; Eka Kurniawan
International Journal of Health and Pharmaceutical (IJHP) Vol. 6 No. 3 (2026): August 2026
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v6i3.681

Abstract

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract associated with significant extraintestinal manifestations. Arthritis is the most frequent extraintestinal manifestation, with an overall prevalence of 17–39%, and is classified as a subtype of spondyloarthritis involving axial and/or peripheral joints. Peripheral arthritis is generally non-erosive, with the oligoarticular variant correlating with intestinal disease activity, whereas axial arthritis—including sacroiliitis and ankylosing spondylitis—tends to progress independently of bowel disease activity. This narrative review aims to provide a comprehensive overview of IBD-associated arthritis, covering its definition, epidemiology, pathogenesis, clinical manifestations, diagnosis, and management. Pathogenesis involves three interconnected mechanisms: extension of intestinal immune responses, gut microbiota dysregulation through Th17 pathway activation, and genetic predisposition mediated by HLA-B27 and NOD2/CARD15. Diagnosis relies on ASAS clinical criteria, with MRI as the preferred modality for early detection of axial involvement. Management requires an integrated approach; TNF-α inhibitors serve as first-line therapy in active disease, while JAK inhibitors, ustekinumab, and vedolizumab represent promising novel therapeutic options. Multidisciplinary collaboration between gastroenterologists and rheumatologists is essential to optimize long-term clinical outcomes.
Co-Authors Eka Kurniawan Iqbal Habibie